Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 4,050
Avg Vol 148,380
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 31%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution se...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 705-719-7425
Address:
151 John Street, Barrie, Canada
1MoneyPaws
1MoneyPaws Jun. 17 at 3:37 PM
$MEDIF $LABS.TSX šŸ’š We voted GREEN — now let’s see GREEN! šŸ’ø We expect results — and we hope that little scare makes you work harder. šŸ˜šŸ‘€ #GreenProxy #InvestorMoves #ShowUsTheMoney #GreenDaysAhead #TimeToDeliver
0 Ā· Reply
1MoneyPaws
1MoneyPaws Jun. 12 at 4:35 AM
$MEDIF $LABS.TSX šŸš€ I Used to Be Team Green... Now I’m Seeing Gold šŸš€ I supported MediPharm’s current management—I thought they were finally steadying the ship. But Apollo just came forward with something different. No hype. Just a bold, measurable plan: šŸ”ø $0.07 āž”ļø Targeting $1+ in 3 years (that’s 10x+) šŸ”ø $0.25 per share in Year One šŸ”ø End golden parachutes & the asset fire-sale šŸ”ø Executive pay tied to performance—not upfront Let’s be real—we’re holding something with serious potential. That’s why there’s a fight over these cheap shares. It’s undervalued, and Apollo clearly knows it. This feels like more than just talk—it’s actual accountability and a strategy with teeth. šŸ—£ I’m curious what other real shareholders think. Are you leaning GOLD too? Or seeing it differently? #ShareholderVoices #MicrocapTurnaround #UndervaluedOpportunity
2 Ā· Reply
Triple_D
Triple_D Jun. 11 at 3:37 PM
$MEDIF sounds better than the shā€@ show we have now
0 Ā· Reply
frontiere
frontiere Jun. 4 at 11:26 AM
$MEDIF MediPharm Labs $LABS.TSX , $CHEK Check-Cap — diagnostics micro/nanocaps — no pstn, watching the Canadian-Israeli shitco drama šŸæ 1- https://www.prnewswire.com/news-releases/apollo-technology-capital-corporation-poses-questions-that-medipharm-shareholders-should-ask-on-managements-conference-call-with-shareholders-302455297.html 2– https://www.globenewswire.com/news-release/2025/06/04/3093435/0/en/Check-Cap-claims-BMO-s-Chris-Taves-Illegally-Attacks-Israeli-NASDAQ-Listed-Company-During-Wartime.html
0 Ā· Reply
DonCorleone77
DonCorleone77 Jun. 4 at 11:16 AM
$CHEK $MEDIF Check-Cap 'publicly condemned' MediPharm Labs, Chairman Chris Taves The company said, "Check-Cap (CHEK) publicly condemned MediPharm Labs (MEDF)) and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time for Israeli Companies.Check-Cap is deeply disturbed that Mr. Taves would leverage the implied authority of his position as a senior BMO Executive to exploit the wartime circumstances currently affecting Israel, in order to knowingly spread false information aimed at harming Check-Cap's reputation, stock price, and business relationships. This conduct is not only unethical and unlawful - it is shameful. Specifically, MediPharm Labs's May 23, 2025 press release quoted Mr. Taves making what Check Cap believes to be demonstrably false statements about Check-Cap. Even more egregious, Mr. Taves, a financial executive who surely knows better, publicly disseminated his accusation of there being deficiencies in our public disclosures, without any actual factual basis whatsoever. Check-Cap believes that Mr. Taves is misusing his position of trust as a BMO Capital Markets Executive to intentionally issue these misleading statements during trading hours in order to manipulate and drive down Check-Cap's stock price, violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934. Check-Cap demands that MediPharm Labs and Mr. Taves immediately retract the defamatory press release, cease all related misleading communications, and publicly apologize for Mr. Taves disgraceful actions. The fact that Mr. Taves and MediPharm Labs have chosen to launch such deplorable and unfounded attacks on an Israeli company minutes before the start of Shabbat at a time of war is reprehensible. Check-Cap will vigorously defend its reputation and its rights against these highly unethical attempts at aspersion, market manipulation and interference in a public transaction."
0 Ā· Reply
1MoneyPaws
1MoneyPaws May. 30 at 11:26 AM
$LABS.TSX $MEDIF Am I crazy for thinking profitability is just around the corner based on these numbers? Why isn’t management making more noise about this? šŸ¤” Given the current revenue growth, improving margins, and reduced operating costs, hitting profitability this year isn’t just wishful thinking — it’s a realistic expectation. šŸ“ˆšŸ’°
0 Ā· Reply
1MoneyPaws
1MoneyPaws May. 22 at 4:14 AM
$LABS.TSX $MEDIF šŸ”„Back in the day, talk was cheap, and respect had a price. You wanted a voice? You put your money down. Now everyone’s yapping, but real players know—only action moves the needle. šŸ’° šŸš€ Apollo’s playing the classic shakeout—rattle the weak hands, then load up while the sidelines second-guess. But when the latecomers come stampeding in—chasing what they once dismissed—it’ll be too late. ā³ šŸŽÆ This isn’t just a game. It’s the art of the move. šŸ’„Game on
0 Ā· Reply
Zackpedia
Zackpedia May. 21 at 8:22 PM
$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .07 today if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 Ā· Reply
Zackpedia
Zackpedia May. 21 at 4:42 PM
$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .075 today if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 Ā· Reply
Zackpedia
Zackpedia May. 20 at 11:43 PM
$LABS.TSX $MEDIF Told you to sell! Down to 8 cents now
0 Ā· Reply
Latest News on MEDIF
No data available.
1MoneyPaws
1MoneyPaws Jun. 17 at 3:37 PM
$MEDIF $LABS.TSX šŸ’š We voted GREEN — now let’s see GREEN! šŸ’ø We expect results — and we hope that little scare makes you work harder. šŸ˜šŸ‘€ #GreenProxy #InvestorMoves #ShowUsTheMoney #GreenDaysAhead #TimeToDeliver
0 Ā· Reply
1MoneyPaws
1MoneyPaws Jun. 12 at 4:35 AM
$MEDIF $LABS.TSX šŸš€ I Used to Be Team Green... Now I’m Seeing Gold šŸš€ I supported MediPharm’s current management—I thought they were finally steadying the ship. But Apollo just came forward with something different. No hype. Just a bold, measurable plan: šŸ”ø $0.07 āž”ļø Targeting $1+ in 3 years (that’s 10x+) šŸ”ø $0.25 per share in Year One šŸ”ø End golden parachutes & the asset fire-sale šŸ”ø Executive pay tied to performance—not upfront Let’s be real—we’re holding something with serious potential. That’s why there’s a fight over these cheap shares. It’s undervalued, and Apollo clearly knows it. This feels like more than just talk—it’s actual accountability and a strategy with teeth. šŸ—£ I’m curious what other real shareholders think. Are you leaning GOLD too? Or seeing it differently? #ShareholderVoices #MicrocapTurnaround #UndervaluedOpportunity
2 Ā· Reply
Triple_D
Triple_D Jun. 11 at 3:37 PM
$MEDIF sounds better than the shā€@ show we have now
0 Ā· Reply
frontiere
frontiere Jun. 4 at 11:26 AM
$MEDIF MediPharm Labs $LABS.TSX , $CHEK Check-Cap — diagnostics micro/nanocaps — no pstn, watching the Canadian-Israeli shitco drama šŸæ 1- https://www.prnewswire.com/news-releases/apollo-technology-capital-corporation-poses-questions-that-medipharm-shareholders-should-ask-on-managements-conference-call-with-shareholders-302455297.html 2– https://www.globenewswire.com/news-release/2025/06/04/3093435/0/en/Check-Cap-claims-BMO-s-Chris-Taves-Illegally-Attacks-Israeli-NASDAQ-Listed-Company-During-Wartime.html
0 Ā· Reply
DonCorleone77
DonCorleone77 Jun. 4 at 11:16 AM
$CHEK $MEDIF Check-Cap 'publicly condemned' MediPharm Labs, Chairman Chris Taves The company said, "Check-Cap (CHEK) publicly condemned MediPharm Labs (MEDF)) and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time for Israeli Companies.Check-Cap is deeply disturbed that Mr. Taves would leverage the implied authority of his position as a senior BMO Executive to exploit the wartime circumstances currently affecting Israel, in order to knowingly spread false information aimed at harming Check-Cap's reputation, stock price, and business relationships. This conduct is not only unethical and unlawful - it is shameful. Specifically, MediPharm Labs's May 23, 2025 press release quoted Mr. Taves making what Check Cap believes to be demonstrably false statements about Check-Cap. Even more egregious, Mr. Taves, a financial executive who surely knows better, publicly disseminated his accusation of there being deficiencies in our public disclosures, without any actual factual basis whatsoever. Check-Cap believes that Mr. Taves is misusing his position of trust as a BMO Capital Markets Executive to intentionally issue these misleading statements during trading hours in order to manipulate and drive down Check-Cap's stock price, violating Section 9(a)(2) of the U.S. Securities Exchange Act of 1934. Check-Cap demands that MediPharm Labs and Mr. Taves immediately retract the defamatory press release, cease all related misleading communications, and publicly apologize for Mr. Taves disgraceful actions. The fact that Mr. Taves and MediPharm Labs have chosen to launch such deplorable and unfounded attacks on an Israeli company minutes before the start of Shabbat at a time of war is reprehensible. Check-Cap will vigorously defend its reputation and its rights against these highly unethical attempts at aspersion, market manipulation and interference in a public transaction."
0 Ā· Reply
1MoneyPaws
1MoneyPaws May. 30 at 11:26 AM
$LABS.TSX $MEDIF Am I crazy for thinking profitability is just around the corner based on these numbers? Why isn’t management making more noise about this? šŸ¤” Given the current revenue growth, improving margins, and reduced operating costs, hitting profitability this year isn’t just wishful thinking — it’s a realistic expectation. šŸ“ˆšŸ’°
0 Ā· Reply
1MoneyPaws
1MoneyPaws May. 22 at 4:14 AM
$LABS.TSX $MEDIF šŸ”„Back in the day, talk was cheap, and respect had a price. You wanted a voice? You put your money down. Now everyone’s yapping, but real players know—only action moves the needle. šŸ’° šŸš€ Apollo’s playing the classic shakeout—rattle the weak hands, then load up while the sidelines second-guess. But when the latecomers come stampeding in—chasing what they once dismissed—it’ll be too late. ā³ šŸŽÆ This isn’t just a game. It’s the art of the move. šŸ’„Game on
0 Ā· Reply
Zackpedia
Zackpedia May. 21 at 8:22 PM
$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .07 today if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 Ā· Reply
Zackpedia
Zackpedia May. 21 at 4:42 PM
$LABS.TSX $MEDIF You could’ve sold when I alerted and bought back at .075 today if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 Ā· Reply
Zackpedia
Zackpedia May. 20 at 11:43 PM
$LABS.TSX $MEDIF Told you to sell! Down to 8 cents now
0 Ā· Reply
PeaceDog
PeaceDog May. 16 at 2:46 PM
$MEDIF It's clear that since David Pidduck took over as CEO in 2022, things have been improving at Medipharm Labs. Pharmaceuticals grade cannabis and synthetic THC (dronabinol). They also have industrial capacity Supercritical CO2 extraction which results in pharmaceutical grade cannabis products. Since Pidduck took over in 2022, the Key Performance Indicators are as clear as can be. Things are looking up for Medipharm Labs!
0 Ā· Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 16 at 1:33 PM
MediPharm Labs ($MEDIF) is burning cash at an alarming rate - $3.3M last quarter alone. With only 6 months of runway left and 21 straight quarters of losses, Apollo Capital's warning rings loud: this ship is sinking without board overhaul. Management's 'rosy outlook' looks increasingly detached from reality. Shareholders face a binary choice at the ballot box. https://www.prnewswire.com/news-releases/apollo-capital-warns-medipharm-shareholders-of-continued-value-destruction-and-insolvency-risk-following-disastrous-q1-financial-results-302457771.html
0 Ā· Reply
PeaceDog
PeaceDog May. 14 at 2:32 PM
$MEDIF Very good report and good earnings call. I'm in.
0 Ā· Reply
Opster216
Opster216 May. 14 at 12:48 PM
$MEDIF Time for a move up. During Q1 2025, the Company's revenue of $10.8M increased $1.0M or 11% versus the three months ended March 31, 2024 ("Q1 2024"), largely driven by the increased revenues generated by sales of flower and dronabinol in our international business
0 Ā· Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 14 at 12:33 PM
$MEDIF's management finally faces accountability after destroying 99% of shareholder value. Apollo Capital's proxy battle highlights critical issues: $1B lost, reckless cash burn, and self-serving compensation. Shareholders get one shot at redemption - vote for new leadership on June 16. Current trajectory points to insolvency. https://www.prnewswire.com/news-releases/apollo-technology-capital-corporation-poses-questions-that-medipharm-shareholders-should-ask-on-managements-conference-call-with-shareholders-302455297.html
0 Ā· Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 14 at 11:34 AM
$MEDIF delivers a standout Q1: 11% revenue growth to $10.8M, 87% surge in international medical sales, and first positive Adjusted EBITDA. Cash position at $8.4M with no debt. Conference call today at 10am ET – perfect timing for management to pop the champagne. https://www.prnewswire.com/news-releases/medipharm-labs-announces-strong-q1-2025-results-302455227.html
0 Ā· Reply
1MoneyPaws
1MoneyPaws May. 13 at 4:00 AM
$MEDIF $LABS.TSX Now that MediPharm is turning things around, outsiders show up claiming they can run it better? šŸ¤” Where were they when we actually needed them? This management team put in the work and rebuilt the company šŸ’Ŗ. Now Apollo wants to swoop in and take credit? If they truly believe in the future, buy the shares šŸ’°. Let’s be real—3% ownership, yet they want six board seats? 🧐 If that’s the logic, I should have a seat myself with the shares I hold! But I won’t, because I back this team. Like it or not, we’ve improved, and it’s thanks to this leadership. If it’s suddenly worth grabbing, pay the market price—no shortcuts. We know exactly what we have. šŸ’Ž Fellas, grab these shares while they’re undervalued šŸ“ˆ. The real ones know what’s coming šŸ”„šŸ’Ž. We didn’t hold just to watch them take it. Value is earned, not seized. Let them pay for it. šŸ’°šŸ”„ Stay Blessed.
0 Ā· Reply
Chancho321
Chancho321 Mar. 25 at 3:22 PM
$MEDIF will this ever go back to over a buck?
0 Ā· Reply
Zackpedia
Zackpedia Mar. 25 at 10:17 AM
$LABS.TSX $MEDIF I sense an offering is coming here pretty soon
1 Ā· Reply
Triple_D
Triple_D Mar. 24 at 2:21 PM
$MEDIF hmmmm what’s up here -keep going you owe me VIVO $$
0 Ā· Reply
1MoneyPaws
1MoneyPaws Mar. 21 at 10:45 PM
The momentum surrounding $LABS.TSX - $MEDIF is undeniableāœØļø Trading volume is surging along with rising prices, indicating a major market shift. For too long, this stock has been tightly controlled and undervalued, but it has finally broken free,šŸ’Æ surpassing key price averages and signaling a promising new chapter.āœ…ļø This isn’t just speculation—this company has emerged from the shadows, securing significant contracts that position it for profitability, not years down the line, but *right now*. The potential for growth is immense, and the fundamentals are stronger than ever. Whether or not official news has surfaced, the trajectory is clear. We’re no longer just holding a sleeper stock—we’re holding a winner. Expect the stock price to begin reflecting the true value of the company as it aligns with its newfound growth and opportunities. For those invested, hold strong. We are just getting started šŸ’Ŗ šŸ™Œ šŸ™ 🐾 ā¤ļø Oh yea, and tell a friend šŸ˜‰
1 Ā· Reply
1MoneyPaws
1MoneyPaws Mar. 19 at 11:59 PM
$LABS.TSX $MEDIF @Zackpedia blocked me… but hey, can someone kindly pass along one (or, better yet, all) of these? šŸ–•šŸ–•šŸ–• And do let him know: "Congrats, Zack! You played yourself. 🤣 Your days of shorting this are officially over—you got fried to a crisp. Remember that little heads-up I gave you last time? Consider this your encore warning: the curtain’s just going up on this show. āœØļø Oh, and one more thing—shareholders here? Yeah, we’re sitting pretty because we know *exactly* what we’ve got. šŸ‘Œ Cheers, buddy!
1 Ā· Reply